Furthermore, in a novel AlbuMus RAG1 knockout model (AlbuMus RAG1 KO) bearing EGFR-positive BRAF mutated tumours, we demonstrate superior anti-tumour effects after a single dose of the Albu-LiTE construct compared to a conventional Fc-less LiTE format and a full-length anti-EGFR monoclonal antibody. The gene discussed is BRAF; the disease is neoplasm.